CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study
Yasuo Suzuki, Mitsuo Iida, Hiroaki Ito, Isamu Saida, Toshifumi Hibi
Intest Res. 2016;14(1):50-59.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.50

Excel Download

Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study
Intestinal Research. 2016;14(1):50   Crossref logo
Link1

Safety and Efficacy of a New 3.3g b.i.d. Tablet Formulation in Patients With Mild-to-Moderately-Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Yearbook of Gastroenterology. 2009;2009:110-111   Crossref logo
Link1 Link2

Mo1786 A Multi-Center, Double-Blind, Placebo Controlled, Parallel Group, Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of the S1P Receptor Modulator Krp203 in Subjects With Moderately Active Refractory Ulcerative Colitis
Gastroenterology. 2016;150(4):S775-S776   Crossref logo
Link1 Link2

Su1125 Long-Term Efficacy of a pH-Dependent Release Mesalamine Formulation, Asacol in Patients With Ulcerative Colitis Who Showed Inadequate Response to a Time-Dependent Release Mesalamine Formulation, Pentasa: A Prospective Study
Gastroenterology. 2014;146(5):S-381-S-382   Crossref logo
Link1 Link2

Safety and Efficacy of a New 3.3 g b.i.d. Tablet Formulation in Patients With Mild-to-Moderately-Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
The American Journal of Gastroenterology. 2009;104(6):1452-1459   Crossref logo
Link1 Link2 Link3

Su1916 RAPID HISTO-ENDOSCOPIC MUCOSAL HEALING WITH (HIGH DOSE) MESALAMINE IN ACTIVE MILD-MODERATE ULCERATIVE COLITIS: POSTHOC ANALYSIS OF POOLED DATA FROM 4 DOUBLE-BLIND, DOUBLE-DUMMY, MULTICENTER, RANDOMIZED TRIALS
Gastroenterology. 2020;158(6):S-701   Crossref logo
Link1 Link2

Sa1112 Long-Term Efficacy of a pH-Dependent Release Mesalamine Formulation, Asacol in Patients With Ulcerative Colitis Who Showed Inadequate Response to a Time- Dependent Release Mesalamine Formulation, Pentasa: A Prospective study
Gastroenterology. 2013;144(5):S-205   Crossref logo
Link1 Link2

Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial
. 2021;   Crossref logo
Link1 Link2

Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial
. 2020;   Crossref logo
Link1 Link2

83 Efficacy and Tolerability of a Once Daily Treatment with Budesonide Capsules Versus Mesalamine Granules for the Treatment of Active Ulcerative Colitis: A Randomized, Double-Blind, Double-Dummy, Multicenter Study
Gastroenterology. 2009;136(5):A-15   Crossref logo
Link1 Link2